HM100714 / Hanmi - LARVOL DELTA

Structure- and bioinformatics-driven development of a selective, orally bioavailable HER2 small molecule inhibitor (HM100714) for cancer therapy (AACR 2026) - "Moreover, structure-based analyses and bioinformatics provided key data that streamline clinical readiness. These preclinical results support HM100714 as a promising therapeutic candidate for HER2-altered cancers."

Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • HER-2

Hanmi Pharmaceutical Presents the Most Research Outcomes at AACR, Innovating Beyond Obesity to Cancer Treatment (Korea IT Times) - "Hanmi Pharmaceutical has announced that it will present the highest number of research outcomes among domestic pharmaceutical and bio companies at the prestigious American Association for Cancer Research (AACR) for three consecutive years, demonstrating the future value of its cancer drug pipeline."

Preclinical • Oncology